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Abstract
Background: Since successful treatment of superficial bladder cancer with BCG requires proper
induction of Th1 immunity, we have developed a rBCG-S1PT strain that induced a stronger cellular
immune response than BCG. This preclinical study was designed to compare the modulatory
effects of BCG and rBCG-S1PT on bladder TNF-α and IL-10 expression and to evaluate antitumour
activity.
Methods:  For Experiment I, the MB49 bladder cancer cell line was used in C57BL/6 mice.
Chemical cauterization of the bladder was performed to promote intravesical tumor implantation.
Mice were treated by intravesical instillation with BCG, rBCG-S1PT or PBS once a week for four
weeks. After 35 days the bladders were removed and weighed. TNF-〈α  and IL-10 cytokine
responses were measured by qPCR. Experiment II was performed in the same manner as
Experiment I, except the animals were not challenged with MB49 tumor cells. Results: rBCG-S1PT
immunotherapy resulted in bladder weight reduction, compared to the BCG and control group.
There were increases in TNF-α in the BCG-treated group, as well as increases in TNF-α and IL-10
mRNA in the rBCG-S1PT group.
Conclusion: These data indicate a significant reduction of bladder tumor volume for the rBCG
group, compared to the BCG and PBS groups. This suggests that rBCG could be a useful substitute
for wild-type BCG and that the potential modulation between TNF-α and IL-10 cytokine
productions may have therapeutic value.
Background
Although the antitumor effects of the Bacillus Calmette
Guerin vaccine (BCG) have long been demonstrated, its
mechanism of action still raises many questions. In 1959,
initial findings were reported of increased resistance to
cancer induced by BCG [1]. Many studies have shown the
relevance of this translational finding for bladder cancer.
In 1976, a report by Morales indicated promising results
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in the treatment of superficial bladder cancer (SBC) with
BCG [2]. More recently, Herr described BCG treatment as
the most successful immunotherapy used for human
tumors [3].
Following transurethral resection (TUR), BCG is consid-
ered an important coadjuvant in the treatment of superfi-
cial bladder cancer. Immunotherapy has also been
superior to intravesical chemotherapy in patients with car-
cinoma in situ (CIS) [4]. BCG instillation has the main
goal of decreasing bladder cancer recurrences and prevent-
ing tumor progression. Consequently, intravesical BCG is
well established in the management of high grade Ta/T1
urothelial carcinoma, as well as CIS [5].
However, numerous obstacles are encountered when
patients undergo intravesical BCG therapy. Treatment fail-
ure, including recurrence and progression, ranges from 40
to 70%, depending on factors such as tumor stage and his-
tology grade [6]. In addition, a significant reason for con-
cern is the high incidence of adverse events related to BCG
immunotherapy. Complications include local or systemic
side effects. The local adverse reactions occur in 27 to 95%
of patients receiving immunotherapy, mostly causing irri-
tative lower urinary tract symptoms. These expected mild
reactions are rarely significant enough to interrupt the
treatment. However, systemic side effects may occur, with
fever (2–17%) being the most common severe adverse
event. Considering both BCG treatment failure and the
potential side effects, researchers have pursued other
agents with similar antitumor activity, which are hoped to
be more efficient and have lower morbidity [7].
Recombinant BCG technology has allowed the construc-
tion of immunotherapeutic agents aimed at specific tar-
gets. The objective is to stimulate the BCG-induced
immune response that is directly related to the antitumor
effect, inhibiting side reactions that do not participate in
this process. This may be achieved by further elucidating
the main steps responsible for the immunotherapeutic
action in bladder cancer. Studies have demonstrated the
importance of the local inflammatory response, which is
characterized by an influx of leukocyte subpopulations,
such as granulocytes, CD4 and CD8 T cells and NK cells,
and granuloma formation. Following this cellular infiltra-
tion, cytokines characterized as part of the T helper types
1 and 2 (Th1 and Th2) immune response can be meas-
ured in the urine and blood of patients. Cytokines
released by BCG stimulation and considered significant
for the antineoplasic response are essentially those related
to Th1 (IL-12, IL-2, TNF-α and IFN-γ), while a BCG inhib-
itory effect is related to the Th2 (IL-10) response [8]. In
experimental studies the effectiveness of BCG against
bladder cancer has been related to the presence of
delayed-type hypersensitivity (DTH). Nadler et al.
observed enhanced DTH when IL-10 was absent, either by
antibody inhibition or through the use of IL-10-deficient
(IL-10-/-) mice [9].
Nascimento et al. constructed a recombinant BCG (rBCG)
expressing the genetically detoxified S1PT (rBCG-S1PT)
fused with the signal sequence and under the control of
the up-regulated Mycobacterium fortuitum ®-lactamase pro-
moter. It has been demonstrated that when compared to
control BCG, rBCG-S1PT is able to elicit a Th1-driving
effect on the immune response induced against mycobac-
terial proteins [10].
Therefore, we propose evaluation of the effectiveness on
tumor reduction of rBCG-S1PT, compared to BCG and
PBS; and evaluation of the immune response profile
focusing on TNF-α (Th1) and IL-10 (Th2) in an orthotopic
bladder cancer animal model [11,12].
Methods
Animals
Ninety female C57BL/6 mice aged six to eight weeks were
provided by the Bioterism Center of the Medical Faculty of
University of São Paulo, Brazil, and maintained at our ani-
mal care facility for one week prior to use. The mice were
kept in a limited access area at a controlled room temper-
ature, with food and water ad libitum. The mice were
divided into groups for two different experiments (with or
without bladder tumor implantation). All experiments
were approved by the institution's ethical board.
BCG
In all experiments, BCG (Moreau) and rBCG-S1PT, kindly
provided by Dr. Luciana C.C. Leite (Butantan Institute),
were prepared according to previously described proce-
dures [10]. Briefly, BCG and rBCG-S1PT were cultured
under uniform conditions in Middlebrook 7H9 supple-
mented with albumin dextrose-catalase broth and incu-
bated at 37°C with 5% CO2 and shaken continuously.
Bacteria were harvested by centrifugation at 2700 × G in a
5810R (Eppendorff, Rexdale, Ontario), washed and
stored in aliquots at -80°C until use. Aliquots were
thawed and the colony former unit (CFU) was deter-
mined before plating onto Middlebrook 7H10 plates.
Tumor cell line
The murine transitional cell carcinoma cell line MB49
(MB49) was a kind gift from Dr. Yi Lou (University of
Iowa, USA). The cells were cultured at 37°C and 5% CO2
in RPMI 1640 supplemented with 10% FBS (Cultilab, São
Paulo, SP, Brazil), 100 U/mL penicillin and 100 μg/mL
streptomycin. Tumor cells were harvested by trypsiniza-
tion and suspended in RPMI 1640 without L-glutamine,
FBS and antibiotics.Journal of Experimental & Clinical Cancer Research 2008, 27:78 http://www.jeccr.com/content/27/1/78
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Orthotopic tumor implantation
Sixty mice were placed under general anesthesia with i.p.
injection of a mixture of xylazine-ketamine (0.1 mL/10 g/
mouse). A 24-gauge Teflon i.v. catheter (Nipro Medical
Ltda, Sorocaba, SP, Brazil) was inserted through the ure-
thra into the bladder using an inert lubricant (sterile con-
tact gel). To prepare the bladder for tumor implantation,
a chemical lesion was induced in the bladder wall by
intravesical instillation of 0.3 M AgNO3 (8 μL). This pro-
moted an adequate and controlled diffuse bladder wall
cauterization. After 10 seconds, the content was washed
out by transurethral infusion of PBS. Then, a suspension
of 2 × 105 viable tumor cells was instilled into the bladder.
Intravesical drug administration
For Experiment I (n = 60), 24 hours after tumor implanta-
tion, intravesical BCG therapy was initiated. Mice were
randomly assigned to either a control group (receiving
PBS) or two treatment groups (receiving BCG or rBCG-
S1PT). The BCG dose was 1 × 106 CFU/mouse once a week
for one month administered periurethrally in a volume of
100 μl while the mice were lightly anesthetized. Experi-
ment II (n = 30) was performed in the same manner as
Experiment I, but the animals did not receive bladder
tumor implantation.
After 35 days, the animals were sacrificed by CO2 inhala-
tion, examined macroscopically for intravesical tumor
(Experiment I), and bladder weight was individually veri-
fied.
Determination of cytokine mRNA expression by qPCR
Total RNA was extracted from the bladder using Trizol®
(GIBCO/BRL Life Technologies, Inc.) according to the
manufacturer's recommendations, and further purified
with RNeasy columns (Qiagen, Valencia, CA, USA). All
samples from the control, BCG and BCG-S1PT groups
were co-processed to eliminate technical variations. Fol-
lowing DNase treatment (Sigma, St Louis, MO, USA), one
microgram of RNA was reverse transcribed using Super-
Script III reverse transcriptase (Invitrogen Corp., Carlsbad,
CA, USA). The quantitative PCR (qPCR) primers used
were: TNF-α ( F:CATCTTCTCAAAATTCGAGTGACAA,
R:TGGGAGTAGACAAGGTACAACCC), IL-10 (F:GGTT-
GCCAAGCCTTATCGGA,  R:ACCTGCTCCACTGCCTT-
GCT) and GAPDH (F:CAACTCACTCAA GATTGTCAG
CAA, R:GGCATGGACTGTGGTCATGA) (IDT, Coralville,
IA, USA). qPCR was performed using an Applied Biosys-
tems 7500 Real Time PCR System (Applied Biosystems
Inc., USA). The reaction mixture contained SYBR Green
PCR Master mix (Applied Biosystems), 0.5 μmol/μl l of
forward and reverse primer and 1 μl of cDNA in a total
volume of 10 μl. Thermocycling conditions were 50°C for
2 min., 95°C for 10 min. and 40 cycles of [95°C for 15
sec., 60°C for 1 min.]. To normalize for inefficiencies in
cDNA synthesis and RNA input amounts, GAPDH mRNA
expression was used. After the PCR was performed, a dis-
sociation/melting curve was constructed in the range of 60
to 95°C. Data were analyzed using the comparative Ct
method (ΔΔCt method) with the following formula: ΔCt
= Ct (target) – Ct (normalized, GAPDH). The comparative
ΔΔCt calculation involved finding the difference between
ΔCt of the BCG and BCG-S1PT groups and the mean value
of the ΔCt from control for each analyzed transcript. Fold
increase in mRNA expression for the BCG groups com-
pared to normal controls was calculated as 2(-ΔΔCtCt) [13].
The RNA from the bladders from Experiment II was aggre-
gated to perform the qPCR. The RNA extracted from blad-
ders with tumor implantation was quantified
individually.
Histology
After gross examination the bladders were fixed in 10%
buffered formalin, routinely processed with paraffin and
stained by Hematoxilin & Eosin staining (HE).
Statistical analysis
The Test of Homogeneity of Variances served as the Lev-
ene Statistic. ANOVA and Multiple Comparisons (Dun-
nett) were used to test for significant differences between
the means. MedCalc 9.3.3.0 (MedCalc Software, Mari-
akerke, Belgium) was used to perform statistical analysis.
Differences were considered statistically significant at p ≤
0.05.
Results
Assessment of Tumors
Considering the animals of Experiment I (n = 60) that
received intravesical instillation of MB49 cells, 53
(88,3%) developed intravesical tumors after the 15-day
period. At that time there was massive growth of a solid
tumor inside the bladder. The mice without tumor
implantation were detached from the experimental.
The bladders were weighed to test the potential antitumor
effect of the intravesical therapy induced by the immunos-
timulatory action. The mean bladder weight with tumor
implantation and PBS treatment was 229.8 mg (SD =
112.0 mg), while the BCG- and rBCG-S1PT-treated mice
had bladders that weighed 137.2 mg (SD = 87.50 mg) and
93.70 mg (SD = 50.90 mg), respectively. The mice from
Experiment II (without MB49 tumor cell implantation)
had a mean bladder weight of 26.7 mg (SD = 5.0 mg). The
ANOVA on log-transformed data and Student-Newman-
Keuls test for all pairwise comparisons demonstrated a
significant difference between the three groups (p  <
0.001). The multiple comparisons test (Dunnett) showed
significant differences between the groups treated with
PBS and BCG (p = 0.007), PBS and rBCG-S1PT (p < 0.001)
and BCG and rBCG-S1PT (p < 0.001) (Fig. 1).Journal of Experimental & Clinical Cancer Research 2008, 27:78 http://www.jeccr.com/content/27/1/78
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Histologically, there was a high grade urothelial solid car-
cinoma composed of large, cubic cells, arranged in solid
nests, with round, hypercromatic nuclei and one or more
nucleoli. Scattered giant, unusual cells were seen in the
tumor. The mitosis rate was high (50/HPF). Superficial
ulceration and necrosis foci were identified. In all cases
the tumor was invaded through the bladder wall, reaching
the muscularis propria. No vascular invasion or
perineural infiltration was observed. The transition to
normal urothelium was evident, and no in situ carcinoma
was identified (Fig. 2A, B).
Expression of cytokine TNF-  and IL-10 mRNA by qPCR
In Experiment I, mice were challenged with MB49 tumor
cells. Treatment with BCG and rBCG-S1PT showed signif-
icantly increased level of TNF-α, but only animals that
received rBCG-S1PT showed a significantly increase in IL-
10 when compared with the control group. Data were
expressed as mean values ± SEM calculated from different
mice (Fig. 3). Also, in Experiment II, without tumor
implantation, the same patterns of expression were
observed for TNF-α and IL-10 (Fig. 4).
Discussion
The antitumor effects of the Bacillus Calmette Guerin vac-
cine (BCG) have long been demonstrated, but its mecha-
nism of action still remains unclear. Bladder tumors are
involved in the immune response due to their cytokine
release. The experimental bladder tumor cell line MB49
does not produce IL-10, which allows examination of its
levels to serve as an indicator of local stimulation. In this
study, IL-10 had increased levels in treated mice, and was
enhanced in the BCG-S1PT group. This interleukin is con-
sidered essential in the immune response towards a Th2
milieu and/or inhibition of Th1 cytokines. IL-10 is also
important in the downregulation of delayed-type hyper-
sensitivity (DHT) [14]. The highest TNF-α level was
observed in the rBCG-S1PT group, characterizing the
acute immune response pattern unleashed by Bacillus. We
speculate that the increased level of IL-10 in this group
could be a counterbalance, modulating the robust
response of TNF-α. On the other hand, several animal
experiments have shown diverse effects regarding the
influence of IL-10 on the cancer immune response.
Depending on the experimental model, IL-10 seems to
favor or inhibit the existence and progression of tumors
[15]. In gastric, colon, lymphomas and renal cell cancer,
increased IL-10 production has been associated with a
negative prognosis. Alternatively, IL-10 can inhibit the
growth of new vessels within the tumor by acting on the
tumor cells and indirectly by influencing infiltrating
immune cells [16].
Interestingly, IL-10 knockout mice exhibit unregulated
inflammatory activity exemplified by enhanced TNF-α
accumulation, which is associated with a variety of patho-
genic outcomes, including endotoxemia and intestinal
inflammation. IL-10 is a suppressor of TNF-α synthesis
and a potent anti-inflammatory cytokine that is present at
the sites of tumors in a wide variety of human cancers,
including transitional cell carcinoma of the bladder. We
thus proposed the evaluation and comparison of the
immune balance responses of TNF-α and IL-10 to rBCG-
S1PT and BCG in an animal model of orthotopic bladder
cancer.
rBCG-S1PT may represent a further step towards improv-
ing the Th1 immune response, especially in light of the
robust TNF-α stimulation in relation to BCG alone. It has
also been discovered that IL-10 is not necessary for the
antitumor effect of BCG, as we observed no difference on
survival between C57BL/6 wild-type and IL-10-/- mice.
Thus, this Th2-related cytokine may be referred to as an
immunosuppressive agent, which down-regulates
cytokine production by Th1 cells [17]. The overstimula-
tion of TNF-α in combination with the increase on IL-10
expression by rBCG-S1PT, suggests a compensatory mech-
anism. This would represent a counterbalance by IL-10
Weight (mg) of bladders from mice instilled weekly with  BCG (n = 18), S1PT (n = 18) or saline (n = 17) after four  weeks of treatment Figure 1
Weight (mg) of bladders from mice instilled weekly 
with BCG (n = 18), S1PT (n = 18) or saline (n = 17) 
after four weeks of treatment. The differences between 
groups were analyzed by one-way ANOVA (p < 0.01) and 
the Student-Newman-Keuls test for all pairwise comparisons 
after log data transformation. The mean bladder weight from 
Experiment I for the control group was 230 ± 110, the BCG 
group was 137 ± 87 and the S1PT group was 93 ± 50. From 
Experiment II (without MB49 tumor cell implantation), the 
mean bladder weight was 26.7 ± 5. p < 0.05 were considered 
statistically significant. Values were obtained from three inde-
pendent experiments.Journal of Experimental & Clinical Cancer Research 2008, 27:78 http://www.jeccr.com/content/27/1/78
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expression, a Th2 cytokine, as a consequence of Th1
enhancement.
These findings exhibit the adequate therapeutic effect of
rBCG-S1PT by significantly reducing the mean bladder
tumor weight when compared to BCG and PBS. Clearly,
the combination of BCG and pertussis toxin may repre-
sent a new pathway by which other forms of rBCG may
improve efficacy against bladder tumor.
Conclusion
The data of this study indicate a significant reduction of
bladder tumor volume in the rBCG group, compared to
BCG and PBS, which may indicate that rBCG could be a
useful substitute for wild-type BCG and suggest that the
potential modulation between TNF-α and IL-10 cytokine
production may have therapeutic value.
A. Infiltrative Urothelial Carcinoma: evidence of multiple foci of lamina propria invasion HE, ×100 Figure 2
A. Infiltrative Urothelial Carcinoma: evidence of multiple foci of lamina propria invasion HE, ×100. B. Infiltrative 
Urothelial Carcinoma: infiltrating cohesive nests of cells with large hyperchromatic nuclei, HE, ×400.
Relative cytokine gene expression in bladders from mice  challenged with MB49 tumor cells and treated with PBS  (white bar), BCG (gray bar) or rBCG-S1PT (black bar), as  determined by q PCR Figure 3
Relative cytokine gene expression in bladders from 
mice challenged with MB49 tumor cells and treated 
with PBS (white bar), BCG (gray bar) or rBCG-S1PT 
(black bar), as determined by q PCR. Data were 
expressed as mean values ± SEM (n = 10).
Relative cytokine gene expression in bladders from mice  without tumor implantation and treated with PBS (white  bar), BCG (gray bar) or rBCG-S1PT (black bar), as deter- mined by qPCR Figure 4
Relative cytokine gene expression in bladders from 
mice without tumor implantation and treated with 
PBS (white bar), BCG (gray bar) or rBCG-S1PT 
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